Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | ABL1 | P00519 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20028848 | 0.80 | NPSR1 (0.32) | BRD4NPSR1KMT2AFTO | |
| SCHEMBL20028324 | 0.76 | SMO (0.37) | BRD4TSHRKMT2A | |
| SCHEMBL20028554 | 0.75 | BRD4 (0.39) | BRD4TSHRKMT2A | |
| SCHEMBL25796422 | 0.66 | F2 (0.47) | TSHRKMT2A | |
| SCHEMBL11061761 | 0.62 | TSHR (0.47) | TSHRKMT2A | |
| SCHEMBL26545466 | 0.62 | F2 (0.45) | TSHRKMT2A | |
| SCHEMBL25845894 | 0.62 | F2 (0.45) | TSHRKMT2A | |
| SCHEMBL28781857 | 0.62 | KMT2A (0.44) | TSHRKMT2A | |
| SCHEMBL25629880 | 0.62 | CHRNA7 (0.56) | TSHRKMT2A | |
| SCHEMBL26019477 | 0.62 | F2 (0.41) | TSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3292125-B1 | HETEROCYCLIC COMPOUNDS AND THEIR USE IN PREVENTING OR TREATING BACTERIAL INFECTIONS | MUTABILIS (FR) | 2019-09-04 | — | — | EP | disclosed |
| US-10183943-B2 | Heterocyclic compounds and their use in preventing or treating bacterial infections | MUTABILIS (FR) | 2019-01-22 | — | — | US | disclosed |
| US-20180093985-A1 | Heterocyclic Compounds and Their Use in Preventing or Treating Bacterial Infections | MUTABILIS (FR) | 2018-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10183943-B2 | Heterocyclic compounds and their use in preventing or treating bacterial infections | NQO1, PEPD, LCT | BRD4 575/4885NPSR1 4152/4885ABL1 823/4885 |
| US-20180093985-A1 | Heterocyclic Compounds and Their Use in Preventing or Treating Bacterial Infections | NQO1, PEPD, LCT | BRD4 575/4885NPSR1 4152/4885ABL1 823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.